Application of biological effective dose (BED) to estimate the duration of symptomatic relief and repopulation dose equivalent in palliative radiotherapy and chemotherapy

被引:18
作者
Jones, B [1 ]
Cominos, M
Dale, RG
机构
[1] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Clin Oncol, London W12 0HS, England
[2] Charing Cross Hosp, Dept Radiat Phys & Radiobiol, London, England
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2003年 / 55卷 / 03期
关键词
radiobiology; linear quadratic model; palliative radiotherapy; cancer therapy;
D O I
10.1016/S0360-3016(02)04284-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To investigate the potential for mathematic modeling in the assessment of symptom relief in palliative radiotherapy and cytotoxic chemotherapy. Methods: The linear quadratic model of radiation effect with the overall treatment time and the daily dose equivalent of repopulation is modified to include the regrowth time after completion of therapy. Results: The predicted times to restore the original tumor volumes after treatment are dependent on the biological effective dose (BED) delivered and the repopulation parameter (K); it is also possible to estimate K values from analysis of palliative treatment response durations. Hypofractionated radiotherapy given at a low total dose may produce long symptom relief in slow-growing tumors because of their low alpha/beta ratios (which confer high fraction sensitivity) and their slow regrowth rates. Cancers that have high alpha/beta ratios (which confer low fraction sensitivity), and that are expected to repopulate rapidly during therapy, are predicted to have short durations of symptom control. The BED concept can be used to estimate the equivalent dose of radiotherapy that will achieve the same duration of symptom relief as palliative chemotherapy. Conclusion: Relatively simple radiobiologic modeling can be used to guide decision-making regarding the choice of the most appropriate palliative schedules and has important implications in the design of radiotherapy or chemotherapy clinical trials. The methods described provide a rationalization for treatment selection in a wide variety of tumors. (C) 2003 Elsevier Science Inc.
引用
收藏
页码:736 / 742
页数:7
相关论文
共 18 条
[1]   THE EFFECT OF OVERALL TREATMENT TIME ON LOCAL-CONTROL IN PATIENTS WITH ADENOCARCINOMA OF THE PROSTATE TREATED WITH RADIATION-THERAPY [J].
AMDUR, RJ ;
PARSONS, JT ;
FITZGERALD, LT ;
MILLION, RR .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1990, 19 (06) :1377-1382
[2]  
[Anonymous], 1999, Radiother Oncol, V52, P111, DOI 10.1016/S0167-8140(99)00097-3
[3]  
Brierley J D, 1996, Clin Oncol (R Coll Radiol), V8, P97, DOI 10.1016/S0936-6555(96)80114-2
[6]  
DALE RG, IN PRESS CLIN ONCOL
[7]   Biological factors influencing optimum fractionation in radiation therapy [J].
Fowler, JF .
ACTA ONCOLOGICA, 2001, 40 (06) :712-717
[8]   THE LINEAR-QUADRATIC FORMULA AND PROGRESS IN FRACTIONATED RADIOTHERAPY [J].
FOWLER, JF .
BRITISH JOURNAL OF RADIOLOGY, 1989, 62 (740) :679-694
[9]   Pain relief and quality of life following radiotherapy for bone metastases: a randomised trial of two fractionation schedules [J].
Gaze, MN ;
Kelly, CG ;
Kerr, GR ;
Cull, A ;
Cowie, VJ ;
Gregor, A ;
Howard, GCW ;
Rodger, A .
RADIOTHERAPY AND ONCOLOGY, 1997, 45 (02) :109-116
[10]   CELL LOSS FACTORS AND THE LINEAR-QUADRATIC MODEL [J].
JONES, B ;
DALE, RG .
RADIOTHERAPY AND ONCOLOGY, 1995, 37 (02) :136-139